Skip to main content
PLOS One logoLink to PLOS One
. 2022 Aug 16;17(8):e0273387. doi: 10.1371/journal.pone.0273387

Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis

Friedemann Schad, Anja Thronicke, Megan L Steele, Antje Merkle, Burkhard Matthes, Christian Grah, Harald Matthes
PMCID: PMC9380908  PMID: 35972953

The following information is missing from the Competing Interests statement:

Dr. Harald Matthes is a member of the board of directors at Weleda AG, a company that until 2016 distributed Iscador, a mistletoe preparation. In addition, Dr. Harald Matthes is a member of the board of the Hufelandgesellschaft e. V. in Germany; President of the DAHN (German Academy for Homeopathy and Naturopathy); and medical director and managing director of Gemeinschaftskrankenhaus Havelhöhe, a hospital for anthroposophic medicine. Dr. Harald Matthes is also a recipient on an endowed professorship from Charité in Berlin on Integrative and Anthroposophical Medicine. These competing interests do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Reference

  • 1.Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C, et al. (2018) Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS ONE 13(8): e0203058. 10.1371/journal.pone.0203058 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES